The board of directors of Transcenta Holding Limited announced encouraging phase I clinical data of TST002 (Blosozumab) in Chinese patients with reduced bone mineral density (BMD). TST002 (Blosozumab) was well tolerated and significantly increased BMD at day 85 following single intravenous injection at various doses. The Company in-licensed the Great China rights of Blosozumab from Eli Lilly and Company ("Eli Lilly") for development and commercialization in Greater China in 2019.

Blosozumab Phase II trials in postmenopausal women in the United States and Japan have been completed by Eli Lilly. The Company conducted a phase I study (NCT05391776) to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single dose of TST002 (BlOSozumab) in Chinese postmenopausal women and elder men with reduced BMD. It was a randomized, double-blind, placebo-controlled, dose-escalation, phase I study with single intravenous injection of TST002 (Bloozumab) at doses of either 200, 400, 800 or 1,200 mg or matching placebo.

A total of 32 patients have been enrolled and treated. Database lock and data unblinding have been completed as of May 12, 2023. Preliminary analysis of the unblinded data shows that the overall safety and tolerability of TST002 (BloSozumab) in all dose cohorts is favorable.

Compared with previous clinical studies of Blosozumab in European, American and Japanese subjects, no new safety signals were found. There were no dose limiting toxicity, SAE, AE led to dose modification or death reported. All the adverse events were transient.

On the efficacy side, all dose cohorts from 200-1,200 mg have shown a clinically meaningful increase in lumbar spine BMD on D85 after a single dose of TST002 ("Blosozumab) and comparable to those of Blosozumab single dose study at the similar dose levels. The average increase of lumbar spine BMD at D85 from baseline ranged from 3.52% to 5.94% across dose cohorts, all exceeding the least significant difference (2.77%). The increase of lumbar spine BMD in the placebo group was only 0.3%.

These results indicate that TST002 (Blosozumab) has the potential to treat osteoporosis, supporting the Company's plan to initiate phase II clinical studies with multiple doses once every two to three months.